Explore Insights on Liquid Tumor Testing for Your Oncology Study

Effective Liquid Tumor Testing for Improved Oncology Trial Outcomes 

Measurement of residual disease is one of the most reliable predictors of treatment outcomes for leukemia, lymphoma, and myeloma. 

Download this insight brief to discover the 8 components of an effective Minimal Residual Disease (MRD) test and explore the comparisonMinimal Residual Disease of measurement approaches for MRD testing, such as:
  • Multicolor flow cytometry
  • Polymerase chain reaction (PCR)
  • Next Generation Sequencing (NGS)
Q2 Solutions offers deep scientific and technical expertise to ensure continued developments in MRD testing. Download our insight brief to learn more about how Q2 Solutions is further positioning MRD as a tool to improve patient care in oncology.

Meet the Authors:
Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More